Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes

Assay and Drug Development Technologies

Volumn 9, Issue 6, 2011, Pages 589-599

  Jonsson, Malin K B ^a   Wang, Qing Dong ^b   Becker, Bruno ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMLODIPINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CARBACHOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIMETHYL SULFOXIDE; ISOPRENALINE; MIBEFRADIL; POTASSIUM CHANNEL HERG; ZATEBRADINE;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CARDIOTOXICITY; CELL ASSAY; CELL DIFFERENTIATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG TARGETING; EMBRYONIC STEM CELL; HEART MUSCLE CELL; HEART PROARRHYTHMIA; HEART RHYTHM; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMPEDANCE CARDIOGRAPHY; IN VITRO STUDY; MOUSE; NONHUMAN; PACEMAKER; PLURIPOTENT STEM CELL; ROOM TEMPERATURE;

ANIMALS; ARRHYTHMIAS, CARDIAC; CALCIUM CHANNEL BLOCKERS; CARDIOTONIC AGENTS; CELLS, CULTURED; ELECTRIC IMPEDANCE; EMBRYONIC STEM CELLS; HUMANS; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PLURIPOTENT STEM CELLS;

EID: 83055173972     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2011.0396     Document Type: Article

References (33)

1. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-716.
2. Jonsson MKB, van Veen TAB, Goumans M-J, Vos MA, Duker G, Sartipy P: Improvement of cardiac efficacy and safety models in drug discovery by the use of stem cell-derived cardiomyocytes. Expert Opin Drug Discov 2009;4:357-372.
3. Nattel S, Duker G, Carlsson L: Model systems for the discovery and development of antiarrhythmic drugs. Prog Biophys Mol Biol 2008;98:328-339.
4. Nerbonne JM, Kass RS: Molecular physiology of cardiac repolarization. Physiol Rev 2005;85:1205-1253. (Pubitemid 41362269)
5. Mangoni M, Nargeot J: Genesis and regulation of heart automaticity. Physiol Rev 2008;88:919-982.
6. Braam SR, Tertoolen L, van de Stolpe A, Meyer T, Passier R, Mummery CL: Prediction of drug-induced cardiotoxicity using human embryonic stem cellderived cardiomyocytes. Stem Cell Res 2010;4:107-116.
7. Caspi O, Itzhaki I, Arbel G, et al.: In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev 2009; 18:161-172.
8. Dick E, Rajamohan D, Ronksley J, Denning C: Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem Soc Trans 2010;38:1037-1045.
9. He JQ, Ma Y, Lee Y, Thomson JA, Kamp TJ: Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res 2003;93:32-39. (Pubitemid 36859038)
10. Jonsson MKB, Duker G, Tropp C, et al.: Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 2010;4:189-200.
11. Moretti A, Bellin M, Welling A, et al.: Patient-specific induced pluripotent stemcell models for long-QT syndrome. N Engl J Med 2010;363:1397-1409.
12. Otsuji T, Minami I, Kurose Y, Yamauchi K, Tada M, Nakatsuji N: Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: qualitative effects on electrophysiological responses to drugs. Stem Cell Res 2010;4:201-213.
13. Pekkanen-Mattila M, Chapman H, Kerkela E, et al.: Human embryonic stem cellderived cardiomyocytes: demonstration of a portion of cardiac cells with fairly mature electrical phenotype. Exp Biol Med 2010;235:522-530.
14. Peng S, Lacerda AE, Kirsch GE, Brown AM, Bruening-Wright A: The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J Pharmacol Toxicol Methods 2010;61:277-286.
15. Yu N, Atienza JM, Bernard J, et al.: Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors. Anal Chem 2005;78:35-43. (Pubitemid 43050137)
16. Ke N, Wang X, Xu X, Abassi Y: The xCELLigence system for real-time and labelfree monitoring of cell viability. Methods Mol Biol 2011;740:33-43.
17. Urcan E, Haertel U, Styllou M, Hickel R, Scherthan H, Reichl FX: Real-time xCELLigence impedance analysis of the cytotoxicity of dental composite components on human gingival fibroblasts. Dent Mater 2010;26:51-58.
18. Itzhaki I, Maizels L, Huber I, et al.: Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471:225-229.
19. Sartiani L, Bettiol E, Stillitano F, Mugelli A, Cerbai E, Jaconi ME: Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells 2007;25:1136-1144. (Pubitemid 46684873)
20. Tanaka T, Tohyama S, Murata M, et al.: In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Comm 2009;385:497-502.
21. Zhang J, Wilson GF, Soerens AG, et al.: Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009;104:e30-e41.
22. Hardy MEL, Pollard CE, Small BG, et al.: Validation of a voltage-sensitive dye (di-4-ANEPPS)-based method for assessing drug-induced delayed repolarisation in Beagle dog left ventricular midmyocardial myocytes. J Pharmacol Toxicol Methods 2009;60:94-106.
23. Liang H, Matzkies M, Schunkert H, et al.: Human and murine embryonic stem cell-derived cardiomyocytes serve together as a valuable model for drug safety screening. Cell Physiol Biochem 2010;25:459-466.
24. Burashnikov A, Antzelevitch C: Acceleration-induced action potential prolongation and early afterdepolarizations. J Cardiovasc Electrophysiol 1998;9:934-948. (Pubitemid 28455963)
25. Goethals M, Raes A, van Bogaert P: Use-dependent block of the pacemaker current I(f ) in rabbit sinoatrial node cells by zatebradine (UL-FS 49). On the mode of action of sinus node inhibitors. Circulation 1993;88:2389-2401. (Pubitemid 23326119)
26. Royer A, Demolombe S, El Harchi A, et al.: Expression of human ERG K F channels in the mouse heart exerts anti-arrhythmic activity. Cardiovasc Res 2005;65:128-137. (Pubitemid 40038485)
27. Stieber J, Wieland K, Stöckl G, Ludwig A, Hofmann F: Bradycardic and proarrhythmic properties of sinus node inhibitors. Mol Pharmacol 2006;69:1328-1337.
28. Lignon JM, Bichler Z, Hivert B, et al.: Altered heart rate control in transgenic mice carrying the KCNJ6 gene of the human chromosome 21. Physiol Genomics 2008;33:230-239. (Pubitemid 351629531)
29. Shan J, Kushnir A, Betzenhauser M, et al.: Phosphorylation of the ryanodine receptor mediates the cardiac fight or flight response in mice. J Clin Invest 2010;120:4388-4398.
30. Viatchenko-Karpinski S, Fleischmann BK, Liu Q, et al.: Intracellular Ca2f oscillations drive spontaneous contractions in cardiomyocytes during early development. Proc Natl Acad Sci USA 1999;96:8259-8264. (Pubitemid 29328442)
31. Burges R. Amlodipine: a once daily calcium antagonist. J Hum Hypertens 1991;5:49-50.
32. Ertel SI, Clozel J-P: Mibefradil (Ro 40-5967): the first selective T-type Ca2f channel blocker. Expert Opin Investig Drugs 1997;6:569-582. (Pubitemid 27225534)
33. Tanaka H, Komikado C, Namekata I, et al.: Species difference in the contribution of T-type calicum current to cardiac pacemaking as revealed by R(f)-efonidipine. J Pharmacol Sci 2008;107:99-102. (Pubitemid 351744088)